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Abstract
Background—The kinetics of the antibody response during severe influenza are not well 
documented.
Methods—Critically ill patients infected with 2009 pandemic influenza A(H1N1) virus 
(A[H1N1]pdm09), confirmed by reverse-transcription polymerase chain reaction analysis or 
seroconversion (defined as a ≥4-fold rise in titers), during 2009–2011 in Canada were 
prospectively studied. Antibody titers in serially collected sera were determined using 
hemagglutinin inhibition (HAI) and microneutralization assays. Average antibody curves were 
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estimated using linear mixed-effects models and compared by patient outcome, age, and 
corticosteroid treatment.
Results—Of 47 patients with A(H1N1)pdm09 virus infection (median age, 47 years), 59% had 
baseline HAI titers of <40, and 68% had baseline neutralizing titers of <40. Antibody titers rose 
quickly after symptom onset, and, by day 14, 83% of patients had HAI titers of ≥40, and 80% had 
neutralizing titers ≥40. Baseline HAI titers were significantly higher in patients who died 
compared with patients who survived; however, the antibody kinetics were similar by patient 
outcome and corticosteroid treatment. Geometric mean titers over time in older patients were 
lower than those in younger patients.
Conclusions—Critically ill patients with influenza A(H1N1)pdm09 virus infection had strong 
HAI and neutralizing antibody responses during their illness. Antibody kinetics differed by age but 
were not associated with patient outcome.
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Certain individuals, including those at the extremes of age or with underlying medical 
conditions, are at high risk of developing severe illness from seasonal influenza virus 
infection. It is unknown whether delayed or deficient antibody responses in individuals 
contribute to their risk of severe illness and death. Studies have suggested that convalescent 
plasma may be useful to treat severe influenza, providing some evidence that the humoral 
immune response may be associated with recovery [1, 2].
Antibodies against influenza viruses can block viral entry, neutralize virus, inhibit viral 
spread, and assist in cell-mediated viral clearance. Antibodies against the hemagglutinin 
protein of influenza viruses correlate with protection against influenza virus infection [3, 4], 
and a hemagglutinin inhibition (HAI) antibody titer of 40 has been shown to correlate with a 
50% reduction in the risk of seasonal influenza virus infection in adults [4–6]. Most studies 
investigating the antibody response during influenza virus infection have focused on 2 time 
points of sera collection relative to symptom onset, but more specimen collection time points 
are needed to fully understand the kinetics of the antibody response during severe influenza 
and the impact of antibody titers on outcomes of infection. The few studies that have 
assessed antibodies from serial blood specimen collections suggest that low antibody titers 
early after influenza virus infection and slow increases in titers are predictive of death from 
fulminant illness [7, 8]. However, these studies are limited by their small sample size and 
unique clinical setting. Identification of immunological markers that can predict outcomes 
early after illness onset could be beneficial in influenza clinical management, but the 
strength of the evidence for using HAI or neutralizing antibody titers as markers of clinical 
severity is currently weak.
In this study, we analyzed the kinetics of the antibody responses in critically ill patients 
admitted to intensive care units (ICUs) with 2009 pandemic influenza A(H1N1) virus 
(A[H1N1]pdm09) infection during the 2009 pandemic and the 2010–2011 influenza season 
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in Canada [9]. We further aimed to examine the association of antibody kinetics and clinical 
outcomes, patient age, and treatment with systemic corticosteroids.
METHODS
Patient Recruitment, Enrollment, and Data Collection
During the 2009 pandemic, Canadian ICU physicians designed and established a multicenter 
cohort of critically ill adolescent and adult patients hospitalized with confirmed, probable, or 
suspected influenza virus infection [9]. Patients were recruited into this cohort from multiple 
sites throughout Canada (see Acknowledgments) between April 2009 and April 2011 from 
both an observational study and an accompanying randomized trial of the effect of high-dose 
oseltamivir (225 mg twice daily) versus standard-dose oseltamivir (75 mg twice daily) on 
influenza viral clearance from the respiratory tract (clinical trials registration 
NCT01010087). Analyses from the current study were blinded to the treatment arm of the 
patients from the randomized trial.
Patients were enrolled into the observational cohort from among all patients admitted to the 
adult ICU with suspected or confirmed influenza. Nonpregnant individuals aged ≥12 years 
who were hospitalized with suspected or confirmed influenza and required ICU admission 
were eligible for the clinical trial. Regardless of study, patients provided informed consent 
for specimen collection and storing blood specimens for future analysis. Blood sample 
collection occurred on days 1, 2, 3, 5, 7, 10, 14, 21, and 28 of hospitalization and at ICU 
discharge if the patient was able to provide blood specimens. Patients could refuse specimen 
collection at any time.
The clinical teams collected information on baseline demographic and clinical features, date 
of symptom onset, use and dates of clinical interventions (including mechanical and 
pharmaceutical interventions), and dates of patient disposition, including discharge from the 
ICU, hospital discharge, or death, as described in the clinical trial protocol [9].
Ethical Approvals
Ethical approval to conduct the clinical trial was provided by each of the participating 
institutions. The use of sera for further testing was approved by the Centers for Disease 
Control and Prevention (CDC).
Laboratory Methods
Blood samples were collected and transported to a central processing laboratory in Canada, 
where they were centrifuged and serum was removed and frozen at −80°C prior to shipment 
to CDC.
HAI assays were performed at CDC as previously described, using 0.5% turkey erythrocytes 
[10]. Serum samples were treated with receptor-destroying enzyme to remove nonspecific 
inhibitors. Nonspecific agglutinins were removed by serum adsorption with packed turkey 
erythrocytes. Serial 2-fold dilutions of sera were made from an initial 1:10 dilution. The 
HAI antibody titer was defined as the reciprocal of the last dilution of serum that completely 
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inhibited hemagglutination, with titers of <10 assigned a value of 5. Final titers were 
reported as the geometric mean of all replicates.
For microneutralization assays, serum samples were first inactivated by heating, and then 
serial 2-fold dilutions were made starting at an initial 1:10 dilution. Influenza virus (100 
50% tissue culture infective doses) was added to serum dilutions, incubated at 37°C with 5% 
CO2 for 1 hour, and used to infect 1.5 × 104 Madin-Darby canine kidney cells per well. 
After over-night incubation, viral infection was quantified by an enzyme-linked 
immunosorbent assay, using monoclonal antibodies specific to the influenza A virus 
nucleoprotein. Neutralizing antibody titers were defined as the reciprocal of the highest 
dilution of serum that yielded at least 50% neutralization. Final titers were reported as 
described for the HAI assay. Egg-propagated wild-type A/Mexico/4108/2009 
A(H1N1)pdm09 virus was used in the HAI and microneutralization assays.
Seroconversion was defined as a ≥4-fold rise in HAI or neutralizing antibody titers between 
any 2 serum specimens, where the second specimen had a titer of ≥40. Influenza A(H1N1) 
pdm09 virus infection was confirmed by detection of viral RNA in respiratory tract 
specimens, using reverse-transcription polymerase chain reaction (RT-PCR) analysis, 
according to local protocols for clinical diagnosis, or evidence of seroconversion by either 
HAI or neutralizing antibodies. A seropositive threshold was defined as an HAI or 
neutralizing antibody titer of 40.
Statistical Analysis
For analysis, corticosteroid doses were converted to prednisone-equivalent dosing by using 
an online calculator [11]. Prednisone-equivalent dosing of ≤50 mg/day was considered low-
dose and >50 mg/day considered high-dose corticosteroid treatment.
Serum samples were considered to have been collected during the acute phase of infection if 
collected ≤10 days after illness onset. Geometric mean antibody titers (GMTs) were 
estimated for patients with blood specimens collected during the intervals of 0–4, 5–10, 11–
14, 15–19, 20–29, 30–39, and ≥40 days after symptom onset. GMTs and 95% confidence 
intervals were plotted by interval and compared by patient age, receipt of corticosteroids 
(either none, low dose, or high dose), and patient outcome (survival or death).
Average antibody curves for log2-transformed HAI and neutralizing titers were estimated 
using linear mixed-effects models among survivors from whom the first blood specimen was 
collected in the acute phase and at least 3 blood specimens were collected during 
hospitalization. This subset included 25 patients with influenza A(H1N1)pdm09 virus 
infection confirmed by RT-PCR or serological analysis. The linear mixed-effects model 
included time as a linear, squared, and cubed term, with random error terms for the intercept 
and a linear term for each patient. This cubic model for antibody titers over time was 
selected after initial inspection of the data and with the understanding that antibody levels 
generally follow a cubic function after illness onset, with an initial rise to a plateau. 
Differences were visually assessed by overlaying observed patient data on the average curve, 
estimated from the linear mixed-effects model. Antibody curves were compared between 
patients who survived and died, by patient age, and by treatment with corticosteroids. The 
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small sample size of the cohort precluded formal statistical comparison of antibody curves 
by patient outcome, age, and corticosteroid therapy.
Two-sided Wilcoxon rank sum tests were used to statistically compare median antibody 
titers by patient outcome, age, and corticosteroid therapy, and the Fisher exact test was used 
to compare frequencies. Data analyses were conducted using SAS, version 9.4. P values of 
<.05 were considered statistically significant.
RESULTS
Eighty-three hospitalized adolescents and adults in Canada with acute respiratory illness and 
suspected influenza were enrolled in either the clinical trial or observational cohort during 
April 2009–May 2010 and during October 2010–April 2011.
Of the 83 patients, 40 had influenza A(H1N1)pdm09 virus infection confirmed by RT-PCR 
analysis, of whom 25 (63%) also had evidence of seroconversion by the HAI or neutralizing 
assays. In addition, 7 patients with respiratory specimens that tested negative by RT-PCR 
analysis for influenza A(H1N1) pdm09 virus had evidence of seroconversion by either HAI 
or neutralizing assays. Therefore, 47 patients had laboratory-confirmed influenza 
A(H1N1)pdm09 virus infection, based on RT-PCR or serologic evidence of infection.
The median age of patients with laboratory-confirmed influenza A(H1N1)pdm09 virus 
infection was 47 years, 17% were aged ≥65 years, 34% were male, and 85% had at least 1 
characteristic that put them at high risk for influenza-associated complications (Table 1). 
Four patients reported that they had been vaccinated against influenza within the last year; 3 
of these patients were likely vaccinated with the 2008–2009 seasonal influenza vaccine, 
which did not include an influenza A(H1N1) pdm09–like virus antigen, and 1 patient was 
likely vaccinated with the 2010–2011 seasonal vaccine, which contained an influenza 
A(H1N1)pdm09–like virus antigen. Patients were hospitalized a median of 5 days after 
illness onset, and all were admitted to an ICU within 2 days of hospital admission (Table 1). 
Ninety-one percent of patients required invasive mechanical ventilation, and 1 patient 
underwent extracorporeal membrane oxygenation. Although data were blinded to the dosage 
given to individual patients, all patients received oseltamivir, and 9 patients received high-
dose oseltamivir (225 mg twice daily). In addition, 52% (25 of 47) received corticosteroid 
therapy during their illness, of whom 60% (15 of 25) received high-dose corticosteroids 
(>50 mg prednisone-equivalent dose). The median time from illness onset to the start of any 
corticosteroid therapy was 5 days (interquartile range [IQR], 2–11 days). High-dose 
corticosteroid therapy was also started a median of 5 days (IQR, 2–9 days) after illness 
onset. The median time of high-dose corticosteroid therapy was 5 days (IQR, 3–8 days).
The median time from onset of symptoms to collection of the first blood specimen was 7 
days (IQR, 5–10 days), and a median of 5 blood samples (IQR, 4–7 samples) were collected 
from each patient during their illness. Of 37 patients with an acute-phase blood specimen 
collected (collected ≤10 days from illness onset), 62% had baseline HAI titers and 68% had 
baseline neutralizing titers of <40. Based on the average antibody curve, estimated among 
survivors with an acute-phase blood specimen collected and at least 3 blood specimens 
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collected, both HAI and neutralizing titers rose quickly over the first 10 days after symptom 
onset and then began to plateau (Figure 1A and 1B). By day 7 after illness onset, 46% of 
patients (11 of 24 with blood samples collected) had an HAI titer of ≥40, and 42% (10 of 24) 
had neutralizing titers of ≥40. By day 14 after illness onset, 83% (34 of 41 with blood 
samples collected) and 80% (33 of 41 with blood samples collected) had HAI and 
neutralizing titers of ≥40, respectively.
Time to collection of the acute-phase blood specimen was similar by patient age (Table 2). 
The frequency of seroconversion, by either HAI or microneutralization assay, was slightly 
lower (63%) among patients aged ≥65 years, compared with 68% of patients aged <50 years 
and 92% of patients aged 50–64 years, although this was not statistically significant (P = .
24). The geometric mean HAI antibody titers in patients aged ≥65 years did not rise as high 
as in younger patients; however, the differences in GMTs by age group were not statistically 
significant (Figure 2).
Of the 20 patients who received any corticosteroid treatment, 5 received low-dose 
corticosteroid therapy, and 15 received high-dose corticosteroid therapy. Among those 
receiving low-dose therapy, 60% (3 of 5 with ≥2 blood specimens collected) experienced 
seroconversion by either HAI or neutralizing antibody titers, which was similar to the 
frequency in those who did not receive corticosteroids (75% of 20 with ≥2 blood specimens 
collected; P = .60). Thirteen patients (93% of 14 with ≥2 blood specimens collected) who 
received high-dose steroid therapy had evidence of seroconversion (P = .36, compared with 
patients with no corticosteroid therapy). There did not appear to be a difference in antibody 
kinetics whether patients were given low-dose or high-dose corticosteroid therapy as 
compared to no corticosteroid treatment (Supplementary Figure 1A and 1B).
Eight patients (19%) with laboratory-confirmed influenza A(H1N1)pdm09 virus infection 
died. Death occurred a median of 19 days (IQR, 17–28 days) after symptom onset. Two 
deaths occurred during the spring pandemic wave (April–July 2009), and 7 deaths occurred 
during the fall pandemic wave (August 2009–May 2010). No deaths occurred among 
patients enrolled during the 2010–2011 influenza season (Table 3). Patients who died had 
significantly higher baseline HAI antibody titers but similar baseline neutralizing antibody 
titers, compared with patients who survived (Table 2). Otherwise, the shape of the antibody 
curves was similar between patients who died and patients who survived (Figure 3). All 8 
patients who died and 85% of patients who survived reached the seropositive threshold for 
HAI antibody titers (P = .57); similarly, 88% of patients who died and 79% of patients who 
survived reached the seropositive threshold for neutralizing antibody titers (P = 1.00). For 
three patients (patients 2, 3, and 5 in Table 3), death appeared to be related to fulminant 
influenza because of the short time after symptom onset. For these individuals, HAI titers 
were ≥40, and neutralizing antibody titers were rising at the time of death for 2 
(Supplementary Figures 2A, 2B, 3A, and 3B).
DISCUSSION
In this study, patients critically ill with influenza A(H1N1) pdm09 virus infection during the 
2009 pandemic and 2010– 2011 influenza season had strong HAI and neutralizing antibody 
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responses against influenza A(H1N1)pdm09 virus during their illness. While the number of 
patients with fatal outcomes was low, we did not observe differences in the antibody 
responses of fatal cases versus survivors. Antibody titers against influenza A(H1N1)pdm09 
virus initially increased rapidly, such that by 2 weeks after symptom onset 83% of patients 
had HAI antibody titers of ≥40. From the average curves, antibody titers appeared to plateau 
after the second week of illness.
The frequency of seroconversion in these critically ill patients was similar to the HAI 
antibody titers described in similar cohorts of critically ill patients and in cross-sectional 
serological studies of patients with influenza A(H1N1)pdm09 virus infection [7, 12–14]. In 
our study, the timing of neutralizing antibody titer rise during illness mirrored the rise in 
HAI antibody titers; however, compared with a study of neutralizing antibodies in serial 
blood specimens from patients infected with influenza A(H7N9) virus, there was a more 
rapid rise in neutralizing antibodies to influenza A(H1N1)pdm09 virus infection in our 
cohort [8]. This difference may be due to immunological priming due to pre-pandemic 
exposure to influenza A(H1N1) viruses among subjects included in this study. However, 
there were also methodologic and population differences between the cohorts that could 
have contributed to differences in measured antibody titers.
The majority of patients in our cohort demonstrated a rise in antibody titers within 2 weeks 
after illness onset; however, some patients did not have increases in antibody titers until 
several weeks later, and 17% and 21% never had HAI or neutralizing antibody titers, 
respectively, that met the seropositive threshold. While most patients with laboratory-
confirmed influenza A(H1N1)pdm09 virus infection included in cross-sectional serological 
studies during the 2009 pandemic had HAI antibody titers of ≥40, 11%–24% did not have 
titers that met this seropositive threshold, even >22 days after illness onset [13, 14]. Among 
a retrospective cohort study of 11 survivors of critical illness from influenza 
A(H1N1)pdm09 virus infection, 2 patients did not have detectable antibodies at any point 
during follow-up, out to 40 days after illness onset [15]. Thus, it appears that a small fraction 
of people will not have a measureable level of strain-specific HAI antibodies despite 
sometimes severe infection and recovery.
The reasons for variation in antibody responses are not fully understood. We found that 
some of this variation may have been age-related as patients aged ≥65 years appeared to 
have lower peak antibody levels, which may reflect immunosenescence. We hypothesized 
that immunomodulatory therapy could also be a source of variability in antibody response. 
The use of corticosteroid treatment in the management of critically ill patients infected with 
influenza A(H1N1)pdm09 infection has been reported to be harmful in most but not all 
observational studies and remains controversial [16–20]. Although corticosteroids may be 
given as immunomodulatory therapy to reduce pulmonary inflammation produced by the 
innate immune response and cytokine dysregulation, immunosuppression from high-dose 
corticosteroid treatment can also result in prolonged influenza viral replication, nosocomial 
bacterial or fungal infection, ventilator-associated pneumonia, and a higher risk of mortality 
due to influenza [16, 18, 19]. However, we found no differences in the antibody responses in 
patients treated with low-dose or high-dose corticosteroids as compared to patients not 
treated with corticosteroids, suggesting that there may not be suppression of the humoral 
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immune response to influenza A(H1N1)pdm09 virus infection, at least within the levels of 
corticosteroids used in these patients.
Antibody titers tend not to be used for clinical management of influenza; however, a French 
study of critically ill patients with influenza A(H1N1)pdm09 virus infection reported that 
the absence of a detectable HAI antibody in blood 4 days after illness onset could predict 
fatal outcome from fulminant disease [7]. Through further laboratory investigations, they 
suggested that the absence of antibodies in the blood was not related to B-cell deficiencies, 
but rather to antibody sequestration in pulmonary immune complexes [7]. In our study, only 
10 individuals (21%) were admitted within 4 days of illness onset, making it challenging to 
evaluate antibody titers on day 4 as an outcome predictor. However, among 3 patients in our 
cohort who likely died from fulminant illness, there was not consistent evidence of low 
antibody titers in acute-phase sera. One of the other 2 patients who likely died from 
fulminant disease had antibody titers of ≥40 on day 3 but only had 2 blood specimens 
collected (on days 3 and 4 after symptom onset), which could not be used to determine 
change in titers. The third patient with fulminant illness had increases in HAI and 
neutralizing antibody titers from the time of first blood specimen collection until the time of 
death, 8 days later. Surprisingly, we did find that patients in our cohort who died had 
significantly higher baseline HAI antibody titers than those who survived. The implications 
of this finding are unclear, as there were small numbers of deaths and the contribution of 
influenza to death could not be fully determined on the basis of the data. However, this 
finding is generally consistent with findings by Monsalvo et al, who reported higher titers of 
influenza A(H1N1)pdm09 virus hemagglutinin–specific immunoglobulin G of relatively 
lower avidity in Brazilian patients with severe illness, compared with those having milder 
influenza A(H1N1)pdm09 virus disease [21].
We were able to detect evidence of seroconversion in 7 patients whose illness was not 
diagnosed on the basis of RT-PCR testing of respiratory specimens during hospitalization 
but who were suspected of having influenza A(H1N1) pdm09 virus infection. This suggests 
that influenza A(H1N1) pdm09 virus infection may have been underdetected in other 
critically ill patients. In studies of critically ill patients during the 2009 pandemic, the 
diagnosis of influenza A(H1N1)pdm09 virus infection was not always made because 
insensitive or nonspecific assays were used or because upper respiratory tract specimens 
were tested after viral shedding had declined [22, 23]. As we observed in this cohort, testing 
paired acute-phase and convalescent-phase sera can yield a retrospective diagnosis of 
influenza virus infection, which is useful for fully ascertaining case patients for clinical and 
epidemiologic studies.
This analysis and our conclusions are subject to limitations. First, because of the long 
duration between symptom onset and death, it is likely that many patients in the cohort died 
from complications of influenza A(H1N1)pdm09 virus infection and not from fulminant 
disease. This may cloud associations between antibody response and influenza-specific 
death, if they exists. Second, the cohort was limited in size, and the number of deaths was 
also few; therefore, we may be underpowered to detect differences for some comparisons. 
Third, our cohort was limited to patients who consented to provide serially collected blood 
specimens. It is possible that patients who died rapidly and likely as a direct result of 
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influenza were not included. Fourth, in this study we only examined humoral immune 
responses. However, future analyses are planned to explore cell-mediated immune 
responses, as cytokine dysregulation and deficiencies in host innate and adaptive immune 
responses have been reported in critically ill patients with influenza A(H1N1)pdm09 virus 
infection [12, 24]. Characterization of the humoral response to older influenza A(H1N1) 
viruses, as well as to other influenza A virus subtypes, may help us explore whether immune 
priming affects severity or recovery from influenza virus infection. Finally, we lacked data 
on influenza A(H1N1)pdm09 viral load and duration of shedding in respiratory specimens to 
assess the impact of the antibody response.
In conclusion, critically ill adolescent and adult patients infected with influenza 
A(H1N1)pdm09 virus during the 2009 pandemic and first postpandemic season showed 
robust antibody responses against influenza A(H1N1)pdm09 virus. The neutralizing 
antibody response mirrored the HAI antibody response, with slight differences by age, but 
responses appeared not to differ on the basis of treatment with high-dose corticosteroids or 
among patients who died. Prospective serial collection of blood specimens from hospitalized 
patients can facilitate understanding of the humoral immune response, as well as the 
adaptive immune response, and should be assessed in future studies to help inform 
understanding of pathogenesis, effectiveness of interventions, and clinical management of 
seasonal influenza and novel influenza A virus infections.
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Figure 1. 
A, Hemagglutinin inhibition (HAI) antibody titers and B, neutralizing antibody titers over 
time for critically ill adolescents and adults hospitalized with influenza A(H1N1)pdm09 
virus infection — Canada, 2009–2011. Average curve was estimated among 25 survivors 
with ≥3 blood draws and at least one acute phase draw, collected ≤10 days after illness 
onset, using an unadjusted cubic linear mixed model. Individual lines are shown for all 47 
enrolled patients with laboratory-confirmed influenza A(H1N1) pdm09 virus infection.
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Figure 2. 
Geometric mean hemagglutinin inhibition (HAI) antibody titers over time for 26 adolescents 
and adults aged <50 years, 13 adults aged 50–64 years, and 9 adults aged ≥65 years 
hospitalized with critical illness due to influenza A(H1N1)pdm09 virus infection — Canada, 
2009–2011. Size of dot is proportionate to the number patients with a blood draw in the time 
interval. Wilcoxon rank sum test comparing the median antibody titer between patients aged 
<50 years and patients aged ≥65 years: P = .64 at 0–10 days, P = .09 at 11–20 days, P = .29 
at 21–30 days, P = .21 at 31–40 days, and P = .60 at >40 days from illness onset.
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Figure 3. 
Hemagglutinin inhibition (HAI) and neutralizing (MN) antibody titer average curves and 
changes over time for 8 critically ill adults who died with influenza A(H1N1)pdm09 virus 
infection — Canada, 2009–2011. Size of dot is proportionate to the number patients with a 
blood draw in the time interval.
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Table 1
Demographic and Clinical Characteristics of 47 Critically Ill Adolescents and Adults Hospitalized With 2009 
Pandemic Influenza A(H1N1) Virus Infection, by Patient Outcome—Canada, 2009–2011
Variable Total Survived Died
Patients 47 (100) 39 (83) 8 (17)
Demographic characteristics
 Influenza season of illness
  Pandemic spring wave (Apr–Jul 2009) 12 (26) 10 (26) 2 (25)
  Pandemic fall wave (Aug 2009–May 2010) 29 (62) 23 (59) 6 (75)
  Oct 2010–Apr 2011 6 (13) 6 (15) 0 (0)
 Age, y 47 (17–80) 48 (17–80) 56 (17–74)
  <50 26 (55) 22 (56) 4 (50)
  50–64 13 (28) 13 (33) 0 (0)
  ≥65 8 (17) 4 (10) 4 (50)
 Sex
  Male 16 (34) 14 (36) 2 (25)
  Female 31 (66) 25 (64) 6 (75)
 Race
  White 29 (62) 25 (64) 4 (50)
  Asian descent 3 (6) 2 (5) 1 (13)
  First Nations 14 (30) 11 (28) 3 (38)
  Other/unknown 1 (2) 1 (3) 0 (0)
Received influenza vaccine 4 (9) 2 (5) 2 (25)
High-risk conditions
 Age ≥65 y 8 (17) 4 (10) 4 (50)
 Chronic lung condition 19 (40) 17 (44) 2 (25)
 Cardiovascular condition 16 (34) 11 (28) 5 (63)
 Renal condition 9 (19) 6 (15) 3 (38)
 Hepatic condition 1 (2) 1 (3) 0 (0)
 Immunosuppression 9 (19) 9 (23) 0 (0)
 Diabetes mellitus 9 (19) 6 (15) 3 (38)
 First Nations 14 (30) 11 (28) 3 (38)
 Obesity (BMI ≥40a) 11 (23) 10 (26) 1 (13)
 Pregnant 3 (6) 2 (5) 1 (13)
 Other 7 (15) 6 (15) 1 (13)
 Any of the above 40 (85) 31 (79) 7 (88)
Clinical characteristics
 Invasive mechanical ventilation use 39 (91) 32 (89) 7 (100)
 ECMO use 1/39 (3) 0/32 (0) 1/7 (14)
J Infect Dis. Author manuscript; available in PMC 2018 March 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rolfes et al. Page 16
Variable Total Survived Died
 Received influenza antiviral therapy 47 (100) 39 (100) 8 (100)
 Received corticosteroid therapy
  Overall 25 (53) 21 (54) 4 (50)
   Low dose
    Received (≤50 mg/d, prednisone equivalent) 14/25 (56) 13/21 (62) 1/4 (25)
    Duration, d 5 (3–7) 4 (3–6) 8 (NA)
  High dose
   Received (>50 mg/d, prednisone equivalent) 15/25 (60) 13/21 (62) 2/4 (50)
   Duration, d 5 (3–8) 5 (3–8) 9 (7–11)
 Pneumonia 13/28 (46) 11/24 (46) 2/4 (50)
 Sepsis 8 (17) 7 (18) 1 (13)
 Shock 19 (40) 15 (38) 4 (50)
  Septic 8 (42) 7 (47) 1 (25)
  Nonseptic 11 (58) 8 (53) 3 (75)
Clinical event duration, d
 From symptom onset to hospitalization 5 (3–8) 5 (3–8) 6 (2–8)
 From hospitalization to ventilation 1 (1–2) 1 (1–2) 3 (1–4)
 From hospitalization to ICU admission 1 (1–2) 1 (1–2) 2 (1–4)
 From symptom onset to discharge or death 28 (18–45) 31 (18–52) 24 (16–31)
 ICU stayb 14 (9–26) 14 (9–26) 17 (12–26)
 Hospital stay 21 (15–31) 24 (16–51) 17 (15–25)
Data are no. or proportion (%) of patients or median value (interquartile range).
Abbreviations: ECMO, extracorporal membrane oxygenation; ICU, intensive care unit; NA, not available.
a
Body mass index (BMI) is calculated as the weight in kilograms divided by the height in meters squared.
bOne patient, a survivor, did not have a known date of ICU discharge.
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